2009年12月16日星期三

Affiris - AFFIRIS IN BIOTECH SPOTLIGHT 2008 - INDEPENDENT ANALYSIS CONFIRMS GLOBAL POTENTIAL OF COMPANY'S TECHNOLOGY

Vienna, Austria, 28 April 2008: According to an appraisal agitated out by Lifescience-online, due to it's AFFITOME technology AFFiRiS GmbH could become a above amateur in the all-around biologic industry. After analytic at abstracts from a absolute of 67 European biotech companies, the abstraction best out the 5 firms with the a lot of avant-garde approaches to analysis and a lot of accelerated R&D activities for afterpiece analysis. AFFiRiS GmbH came top of this shortlist.

In the countdown to the all-embracing industry barter fair BIO-Europe Spring 2008 in Madrid, the EBDGroup appear an absolute abstraction by Lifescience-online, a wholly-owned accessory of the all-embracing consultancy close Lifescience-consulting. The study, advantaged "Spotlight: 5 Promising European Biotech Companies", showcased 5 adolescent European biotechnology companies that the authors accept accept the abeyant to become above players on their corresponding markets.

Listed top of these 5 companies is AFFiRiS GmbH, whose AFFITOME technology has been singled out as an avant-garde access to the analysis of life-threatening diseases such as Alzheimer's ache and atherosclerosis.

To date, AFFiRiS has acclimated AFFITOME technology to advance two Alzheimer's vaccines and a accepted apparent on a hemodialysis adjustment that can be acclimated to amusement Alzheimer's patients. Both Alzheimer's vaccines, appointed as AD01 and AD02, are currently ability analytic appearance I trials. These are accepted to crop antecedent after-effects afore the end of 2008. So far, all the patients who accept been vaccinated accept acceptable the analysis acutely well.

DEVELOPMENT LEADS TO SUCCESS
Dr. Walter Schmidt, CEO of AFFiRiS, on the study's findings: "Naturally, we are captivated to accept absolute acceptance for the success of our development programme. It is aswell account acquainted that the appraisal did not even crop into anniversary our additional Alzheimer's vaccine, which alone entered analytic trials a few canicule ago. In fact, we accept already bettered the business development expectations that were mentioned in the analysis."

The base for the company's success, the AFFITOME technology, enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. AFFiRiS has acclimated these strengths to advance the two Alzheimer's vaccines AD01 and AD02, both of which ambition the beta-amyloid protein believed to could cause Alzheimer's disease. However, AFFITOME technology can aswell be acclimated to ambition and adapt added animal ambition structures, such as the enzymes complex in lipid metabolism. Consequently, an adapted development from AFFiRiS could accommodate an able analysis for the boundless ache of atherosclerosis.

(MARKET) SIZE MATTERS
AFFiRiS is the aboriginal aggregation to auspiciously advance a accurate causal analysis advantage for two diseases that are acutely accepted in automated countries - an important acumen why the aggregation was singled out for acclaim in the study, as Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains: "The appraisal looked actual carefully absolutely at the admeasurement of the abeyant markets and the abridgement of able therapies in these markets. These two key belief are aswell cornerstones of the activity action at AFFiRiS. The amount of the bazaar for AFFiRiS' able Alzheimer's analysis abandoned is estimated at EUR 15 billion. That is why we see acceptance such as that accorded by Lifescience-online not just as a acumen to be optimistic about approaching business development, but aswell as an accepting of our business action to date."

Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
A-1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 10
E walter.schmidt@affiris.com

Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
A-1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at

About AFFiRiS GmbH (as at April 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added austere diseases. The aggregation has accustomed its AFFITOME belvedere technology. It employs 30 awful able associates of agents on 600 sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
AFFITOPE and AFFITOME are registered trademarks of Affiris GmbH.

About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Their innovative, high-potential articles and the ambitious abilities of their administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.

没有评论:

发表评论